Beijing Biostar Pharmaceuticals Co Ltd is a Chinea-based company principally engaged in the research, development, production and sales of innovative drugs. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market.

© Copyright 1996-20220232 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.